HereS a significantly expanded and rewritten news feature based on the provided source material, adhering to all specified guidelines and incorporating best practices for AP style, E-E-A-T, and reader engagement.
Typhoid Vaccine Market Set for Explosive Growth, Driven by Rising Cases and Innovative Technologies
BURLINGAME, CA, April 17, 2025 – the global market for typhoid fever vaccines is projected to surge to $884.8 million by 2030, according to a new report, marking a compound annual growth rate (CAGR) of 12.2% from 2022. This dramatic expansion reflects increasing global health concerns, particularly in developing nations, and the adoption of newer, more effective vaccine technologies.
The report highlights that the typhoid fever vaccines market size was valued at $351.4 million in 2022.Typhoid fever, a systemic infection caused by Salmonella Typhi bacteria, remains a significant public health challenge, especially in regions with poor sanitation and limited access to clean water. The World Health Organization (WHO) estimates around 9 million people are affected by typhoid fever each year, leading to approximately 110,000 deaths annually. “The alarming rise in typhoid fever cases and mortality rates is fueling demand for typhoid fever vaccines, and the trend will likely continue in the coming years,” the report stated.
capsular Polysaccharide Vaccines Lead, Conjugate Vaccines Gaining Ground
currently, capsular polysaccharide vaccines hold the largest market share. According to the report, it “accounted for about 54.8% of the global typhoid fever vaccines market share in 2022.” These vaccines have been a mainstay in typhoid prevention for decades.
however, typhoid conjugate vaccines (TCVs) are swiftly gaining popularity due to their enhanced efficacy and longer-lasting immunity. Unlike older vaccines, TCVs are effective in children under two years of age, a particularly vulnerable population. the increasing adoption of TCVs is expected to positively impact the overall market value.
Regional Hotspots: africa Leads Demand, Asia Pacific Poised for Growth
Africa currently leads in typhoid fever vaccine demand, accounting for a notable 18.8% share of the market in 2022. This reflects the high prevalence of the disease in many African countries.
The Asia Pacific region is anticipated to witness robust growth, fueled by rising typhoid incidence and favorable government immunization initiatives. Several countries in the region are implementing mass vaccination programs to combat the disease.
North America, according to the report, “accounts for the second-largest market share.”
U.S. Focus: Travel and Public Health Initiatives
In the United States, typhoid vaccination is primarily recommended for travelers to endemic regions. The Centers for Disease Control and Prevention (CDC) provides detailed guidelines on travel vaccines,including recommendations for typhoid. While typhoid is not a widespread concern within the U.S., imported cases remain a risk, necessitating vaccination for those traveling to high-risk areas.
Moreover, public health initiatives within certain at-risk communities in the U.
